MRT-55811
/ Monte Rosa Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 20, 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
(GlobeNewswire)
- "MRT-55811 demonstrated superior selectivity compared with clinical-stage CDK2 inhibitors, which exhibited significant off-target activity, as evidenced by kinome profiling and genetic modeling. In CCNE1-amplified cancer cell lines, MRT-55811 selectively inhibited cellular proliferation, while sparing cell lines without amplification."
Preclinical • Solid Tumor
1 to 1
Of
1
Go to page
1